Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025085 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05025085 is a Phase 1 study that has completed, run by Agenus. The registered enrollment target is 25 participants.
The verdict
NCT05025085, a Phase 1 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.
Interventions
- DRUG AGEN1777
- DRUG a PD-1 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05025085
The ClinicalTrials.gov registry entry for NCT05025085 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGEN1777 is the first listed.
NCT05025085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05025085 about?
NCT05025085 is a clinical study titled "A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors". This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.
What is the current status of trial NCT05025085?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-10-04. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT05025085?
The interventions under investigation include: AGEN1777 (DRUG), a PD-1 inhibitor (DRUG).
Who is sponsoring clinical trial NCT05025085?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.